ALK-Abelló A/S (FRA:4AJ0)

Market Cap	6.21B +3.6%
Revenue (ttm)	913.42M +16.5%
Net Income	181.37M +35.7%
EPS	0.82 +36.4%
Shares Out	n/a
PE Ratio	34.24
Forward PE	29.69
Dividend	0.21 (0.77%)
Ex-Dividend Date	Mar 17, 2026

Volume	n/a
Open	27.94
Previous Close	28.02
Day's Range	27.94 - 28.18
52-Week Range	26.22 - 36.28
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 17, 2026

About ALK-Abelló

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1923
• Employees: 2,773
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4AJ0

Financial Performance

In 2025, ALK-Abelló's revenue was 6.31 billion, an increase of 14.00% compared to the previous year's 5.54 billion. Earnings were 1.20 billion, an increase of 46.87%.

Financial numbers in DKK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 4, 2026

Data Sources Report a data error